Aenova Transfers Manufacturing Facility Back to Vectura Group
The lease of the manufacturing facility and oral product business in Saint-Quentin-Fallavier, Lyon, France of Vectura Group, a Chippenham, UK-based drug-delivery company, which had been leased to Aenova France SAS, a contract development and manufacturing organization, expired on June 30, 2016, and the facility transferred back to the Vectura Group upon expiry.
The facility currently manufactures seven oral products for the group’s partners. Five products use the Geomatrix family of technologies: Diclofenac-ratiopharm-uno, Coruno, Zyflo CR, Madopar DR/Prolopa, and Sular while Lodotra/Rayo uses the Geoclock chronotechnology. The facility also manufactures one other oral product, Triglide, based on the group’s solubilization technology. In addition, there are currently a number of pipeline projects in development, including the first complex oral generic under the group’s strategic partnership with Hikma Pharmaceuticals (SKP-1056). The facility has cGMP status, with approvals from the European Medicines Agency, the US Food and Drug Administration, ANVISA (Brazil) and KFDA (South Korea).
Source: Vectura Group